Combination therapy of a type II antiCD20 antibody with a proteasome inhibitor

Details for Australian Patent Application No. 2008315926 (hide)

Owner F. Hoffmann-La Roche AG Roche Glycart AG

Inventors Fertig, Georg; Klein, Christian; Friess, Thomas; Umana, Pablo

Agent Davies Collison Cave

Pub. Number AU-A-2008315926

PCT Pub. Number WO2009/053038

Priority 07020820.2 24.10.07 EP

Filing date 22 October 2008

Wipo publication date 30 April 2009

International Classifications

A61K 31/00 (2006.01)

A61K 39/395 (2006.01) Medicinal preparations containing antigens or antibodies - Antibodies

A61P 35/00 (2006.01) Antineoplastic agents

Event Publications

29 April 2010 PCT application entered the National Phase

  PCT publication WO2009/053038 Priority application(s): WO2009/053038

1 November 2012 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(a). A direction to request examination has been given for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2008315929-Identification of tumor-associated markers for diagnosis and therapy

2008315917-Inverse emulsion polymers containing a polymeric coagulant